The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares some insights into the safety and efficacy of teclistamab in patients with triple-class exposed relapsed/refractory (R/R) myeloma as observed in the MajesTEC-1 trial (NCT04557098), and further highlights the importance of optimizing treatment with this bispecific T-cell engager (BiTE). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
